{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:33:31Z","timestamp":1790732011394,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 DK-52962"],"award-info":[{"award-number":["R01 DK-52962"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012127","name":"Augusta University","doi-asserted-by":"publisher","award":["R41 HL-136068"],"award-info":[{"award-number":["R41 HL-136068"]}],"id":[{"id":"10.13039\/100012127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bcmd.2021.102626","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:00:24Z","timestamp":1637132424000},"page":"102626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Novel histone deacetylase inhibitor CT-101 induces \u03b3-globin gene expression in sickle erythroid progenitors with targeted epigenetic effects"],"prefix":"10.1016","volume":"93","author":[{"given":"Louis H.","family":"Junker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biaoru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingguo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivanagireddy","family":"Koti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan E.","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford L.","family":"Hendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Sangerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perrine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty S.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcmd.2021.102626_bb0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00005792-200109000-00007","article-title":"Pharmacologic modulation of fetal hemoglobin, medicine","volume":"80","author":"Steinberg","year":"2001","journal-title":"(Baltimore)"},{"issue":"15","key":"10.1016\/j.bcmd.2021.102626_bb0010","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2010-11-316893","article-title":"Transcriptional regulation of fetal to adult hemoglobin switching new therapeutic opportunities","volume":"117","author":"Wilber","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcmd.2021.102626_bb0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trsl.2014.05.002","article-title":"Epigenetic regulation of fetal globin gene expression in adult erythroid cells","volume":"165","author":"Ginder","year":"2015","journal-title":"Translat Res"},{"issue":"2","key":"10.1016\/j.bcmd.2021.102626_bb0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hoc.2013.11.009","article-title":"Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies","volume":"28","author":"Perrine","year":"2014","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.bcmd.2021.102626_bb0025","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia","volume":"105","author":"Uda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bcmd.2021.102626_bb0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bcmd.2008.06.007","article-title":"BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies","volume":"41","author":"Sedgewick","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.bcmd.2021.102626_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.1988.tb07607.x","article-title":"Sickle cell-hereditary persistence of fetal haemoglobin and its differentiation from other sickle cell syndromes","volume":"69","author":"Murray","year":"1988","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2021.102626_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-88-1-1","article-title":"Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects","volume":"88","author":"Perrine","year":"1978","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2021.102626_bb0045","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.bcmd.2021.102626_bb0050","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia, investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2021.102626_bb0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5-year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.bcmd.2021.102626_bb0060","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1182\/bloodadvances.2021005076","article-title":"Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy","volume":"5","author":"Dhar","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.bcmd.2021.102626_bb0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 Trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcmd.2021.102626_bb0070","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102626_bb0075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcmd.2021.102626_bb0080","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood.V90.2.891","article-title":"Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease","volume":"90","author":"Selby","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcmd.2021.102626_bb0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199301143280202","article-title":"A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders","volume":"328","author":"Perrine","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102626_bb0090","first-page":"1790","article-title":"Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease","volume":"93","author":"Atweh","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102626_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-4613-0623-8_18","article-title":"Butyric acid modulates developmental globin gene switching in man and sheep","volume":"271","author":"Perrine","year":"1989","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.bcmd.2021.102626_bb0100","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood.V84.12.4344.bloodjournal84124344","article-title":"Alpha-amino butyric acid cannot reactivate the silenced gamma gene of the beta locus YAC transgenic mouse","volume":"84","author":"Pace","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102626_bb0105","first-page":"229","article-title":"Scriptaid, a novel histone deacetylase inhibitor induces gamma-globin gene expression in erythroid progenitors","volume":"51","author":"Johnson","year":"2005","journal-title":"Cell Mol. Biol."},{"issue":"12","key":"10.1016\/j.bcmd.2021.102626_bb0110","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1182\/blood-2009-02-204990","article-title":"The HDAC inhibitors trichostatin a and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice","volume":"115","author":"Hebbel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102626_bb0115","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/ja7110064","article-title":"Structure and activity of Largazole, a potent antiproliferative agent from the Floridian Marine Cyanobacterium Symploca sp.","volume":"130","author":"Taori","year":"2008","journal-title":"J Am Chem Soc."},{"key":"10.1016\/j.bcmd.2021.102626_bb0120","doi-asserted-by":"crossref","first-page":"11219","DOI":"10.1021\/ja8033763","article-title":"Total synthesis and biological mode of action of Largazole: a potent class I histone deacetylase inhibitor","volume":"130","author":"Bowers","year":"2008","journal-title":"J Am Chem Soc."},{"issue":"8","key":"10.1016\/j.bcmd.2021.102626_bb0125","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1021\/ja807772w","volume":"131","author":"Bowers","year":"2009","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.bcmd.2021.102626_bb0130","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.3324\/haematol.2017.185967","article-title":"Fetal hemoglobin induction in sickle erythroid progenitors using a synthetic zinc finger DNA-binding domain","volume":"103","author":"Li","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bcmd.2021.102626_bb0135","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.3324\/haematol.2016.160788","article-title":"NRF2 mediates \u03b3-globin gene regulation and fetal hemoglobin induction in human erythroid progenitors","volume":"102","author":"Zhu","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl_1","key":"10.1016\/j.bcmd.2021.102626_bb0140","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood.V130.Suppl_1.960.960","article-title":"Loss of NRF2 function exacerbates the pathophysiology of sickle cell disease in a transgenic mouse model","volume":"130","author":"Zhu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102626_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ddtec.2015.10.008","article-title":"Screening and profiling assays for HDACs and sirtuins","volume":"18","author":"Howitz","year":"2015","journal-title":"Drug Discov. Today Technol."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102626_bb0150","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1097-2765(02)00781-5","volume":"10","author":"Tolhuis","year":"2002","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.bcmd.2021.102626_bb0155","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/blood-2006-01-023713","article-title":"Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2","volume":"108","author":"Sangerman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102626_bb0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.bb.14.060185.001323","article-title":"Sickle hemoglobin polymerization in solution and in cells","volume":"14","author":"Nobuchi","year":"1985","journal-title":"Annu. Rev. Biophys. Chem."},{"issue":"12","key":"10.1016\/j.bcmd.2021.102626_bb0165","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102626_bb0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2015.10.004","article-title":"Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms","volume":"56","author":"Dai","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102626_bb0175","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41419-018-0679-6","article-title":"Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition","volume":"9","author":"Jing","year":"2018","journal-title":"Cell Death Dis."},{"issue":"28","key":"10.1016\/j.bcmd.2021.102626_bb0180","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1073\/pnas.1006774107","article-title":"Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease","volume":"107","author":"Bradner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.bcmd.2021.102626_bb0185","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2015-03-635391","article-title":"Phase 1\/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea","volume":"125","author":"Okam","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2021.102626_bb0190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1586\/ehm.11.24","article-title":"Clinical development of panobinostat in classical Hodgkin\u2019s lymphoma","volume":"4","author":"Oki","year":"2011","journal-title":"Expert. Rev. Hematol."},{"issue":"17","key":"10.1016\/j.bcmd.2021.102626_bb0195","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood-2012-11-466227","article-title":"Mi2beta-mediated silencing of the fetal gamma-globin gene in adult erythroid cells","volume":"121","author":"Amaya","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcmd.2021.102626_bb0200","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2011.043265","article-title":"Erythroid phenotypes associated with KLF1 mutations","volume":"96","author":"Borg","year":"2011","journal-title":"Haematologica"},{"issue":"7577","key":"10.1016\/j.bcmd.2021.102626_bb0205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2021.102626_bb0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bcmd.2008.12.003","article-title":"BCL11A represses HBG transcription in K562 cells","volume":"41","author":"Chen","year":"2009","journal-title":"Blood Cells Mols Dis."},{"issue":"6270","key":"10.1016\/j.bcmd.2021.102626_bb0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"issue":"5909","key":"10.1016\/j.bcmd.2021.102626_bb0220","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcmd.2021.102626_bb0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.3101","article-title":"Lysine specific demethylase 1 is a therapeutic target for fetal hemoglobin induction","volume":"19","author":"Shi","year":"2013","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bcmd.2021.102626_bb0230","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ng.637","article-title":"KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching","volume":"42","author":"Zhou","year":"2010","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bcmd.2021.102626_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059890","article-title":"Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells","volume":"8","author":"Kurita","year":"2013","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.bcmd.2021.102626_bb0240","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1073\/pnas.1015341108","article-title":"p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex","volume":"108","author":"Gnanapragasam","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.bcmd.2021.102626_bb0245","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1073\/pnas.0509322103","article-title":"Methyl binding domain protein 2 mediates gamma-globin gene silencing in adult human betaYAC transgenic mice","volume":"103","author":"Rupon","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"25","key":"10.1016\/j.bcmd.2021.102626_bb0250","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","article-title":"Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine-thalassemia","volume":"123","author":"Suragani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102626_bb0255","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.3524","article-title":"Targeting a new regulator of erythropoiesis to alleviate anemia","volume":"20","author":"Paulson","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2021.102626_bb0260","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.bcmd.2021.102626_bb0265","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcmd.2021.102626_bb0270","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ajh.24019","article-title":"Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation","volume":"90","author":"Esrick","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.bcmd.2021.102626_bb0275","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2020.12.001","article-title":"Epigenetic regulation of hemoglobin switching in non-human primates","volume":"58","author":"Molokie","year":"2021","journal-title":"Semin. Hematol."},{"issue":"5558","key":"10.1016\/j.bcmd.2021.102626_bb0280","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.1067799","article-title":"Capturing chromosome conformation","volume":"295","author":"Dekker","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2021.102626_bb0285","series-title":"The Molecular Basis of Blood Disease","article-title":"Hemoglobin switching","author":"Stamatoyannopoulos","year":"2001"},{"key":"10.1016\/j.bcmd.2021.102626_bb0290","first-page":"1171","article-title":"Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin","author":"Henry","year":"2021","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:13Z","timestamp":1761050173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979621000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"alternative-id":["S1079979621000929"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102626","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel histone deacetylase inhibitor CT-101 induces \u03b3-globin gene expression in sickle erythroid progenitors with targeted epigenetic effects","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102626"}}